Ask AI
ProCE Banner Activity

Experts Discuss CELMoD Agents for Treating Multiple Myeloma

Podcast Episodes

Listen to Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Niels van de Donk, MD, PhD, address key questions on CELMoD agent therapy for multiple myeloma, including combination strategies, adverse event management, and where CELMoD agents may best fit within current and future treatment strategies.

Released: December 30, 2025

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals who care for patients with multiple myeloma. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate how differences in cereblon affinity and binding potency influence the antimyeloma activity of individual CELMoDs and IMiDs

  • Appraise emerging data for CELMoDs and their potential therapeutic roles across the disease continuum of multiple myeloma

  • Assess the clinical implication and association of achieving MRD negativity on treatment as a surrogate marker of long-term outcomes

  • Identify patients with multiple myeloma who may be eligible for ongoing clinical trials of CELMoD-based therapies

Disclosure

Primary Author

Jesus Berdeja, MD: researcher (paid to institution): AstraZeneca, Bristol Myers Squibb, C4 Therapeutics, Caribou Biosciences, CARsgen, Cartesian, Genentech, GlaxoSmithKline, Gracell, Ichnos Sciences, Johnson & Johnson, Juno, K36 Therapeutics, Karyopharm, Kite, Moderna, Pfizer, Regeneron, Roche, Sanofi; consultant: AstraZeneca, Bristol Myers Squibb, Galapagos, Johnson & Johnson, Kite, Kyowa Kirin, Pfizer, Regeneron, Roche, Sebia; speaker: Janssen.

Amrita Krishnan, MD, FACP: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche, Sanofi; individual publicly traded stock/stock options: Arcellx, Bristol Myers Squibb.

Niels van de Donk, MD, PhD: researcher: Amgen, Bristol Myers Squibb, Celgene, Cellectis, Janssen, Novartis; advisor (paid to institution): AbbVie, Adaptive, Amgen, Bayer, Bristol Myers Squibb, Celgene, Galapagos, Janssen, Kite, Merck, Novartis, Pfizer, Roche, Sanofi, Servier, Takeda.